000163648 001__ 163648
000163648 005__ 20240229123154.0
000163648 0247_ $$2doi$$a10.1002/cam4.3454
000163648 0247_ $$2pmid$$apmid:32960498
000163648 0247_ $$2altmetric$$aaltmetric:91034741
000163648 037__ $$aDKFZ-2020-01926
000163648 041__ $$aeng
000163648 082__ $$a610
000163648 1001_ $$0P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aZheng, Guoqiao$$b0$$eFirst author$$udkfz
000163648 245__ $$aRate differences between first and second primary cancers may outline immune dysfunction as a key risk factor.
000163648 260__ $$aHoboken, NJ$$bWiley$$c2020
000163648 3367_ $$2DRIVER$$aarticle
000163648 3367_ $$2DataCite$$aOutput Types/Journal article
000163648 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683892679_20082
000163648 3367_ $$2BibTeX$$aARTICLE
000163648 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163648 3367_ $$00$$2EndNote$$aJournal Article
000163648 500__ $$a#EA:C050#LA:C050#LA:C020#                    / 2020 Nov;9(21):8258-8265
000163648 520__ $$aMany cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC.We used the Swedish Cancer Registry (1990-2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC-SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC.Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non-Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC.Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification.
000163648 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000163648 588__ $$aDataset connected to CrossRef, PubMed,
000163648 7001_ $$aSundquist, Kristina$$b1
000163648 7001_ $$aSundquist, Jan$$b2
000163648 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b3$$udkfz
000163648 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b4
000163648 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b5$$eLast author$$udkfz
000163648 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.3454$$gp. cam4.3454$$n21$$p8258-8265$$tCancer medicine$$v9$$x2045-7634$$y2020
000163648 909CO $$ooai:inrepo02.dkfz.de:163648$$pVDB
000163648 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163648 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000163648 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000163648 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000163648 9141_ $$y2020
000163648 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2018$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2020-01-09
000163648 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-09
000163648 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-09
000163648 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000163648 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000163648 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000163648 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000163648 980__ $$ajournal
000163648 980__ $$aVDB
000163648 980__ $$aI:(DE-He78)C050-20160331
000163648 980__ $$aI:(DE-He78)B062-20160331
000163648 980__ $$aI:(DE-He78)HD01-20160331
000163648 980__ $$aI:(DE-He78)C020-20160331
000163648 980__ $$aUNRESTRICTED